adamantylamide-alanyl-isoglutamine has been researched along with Moraxella Infections in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Becker, PD; Bertot, GM; Ebensen, T; Grinstein, S; Guzmán, CA; Souss, D | 1 |
1 other study(ies) available for adamantylamide-alanyl-isoglutamine and Moraxella Infections
| Article | Year |
|---|---|
Intranasal vaccination with recombinant outer membrane protein CD and adamantylamide dipeptide as the mucosal adjuvant enhances pulmonary clearance of Moraxella catarrhalis in an experimental murine model.
Topics: Adhesins, Bacterial; Adjuvants, Immunologic; Administration, Intranasal; Amantadine; Animals; Antibodies, Bacterial; Bacterial Vaccines; Cell Proliferation; Colony Count, Microbial; Dipeptides; Disease Models, Animal; DNA, Bacterial; Immunoglobulin A, Secretory; Interferon-gamma; Interleukins; Lung; Lymphocytes; Mice; Mice, Inbred BALB C; Molecular Sequence Data; Moraxella catarrhalis; Moraxellaceae Infections; Mucous Membrane; Spleen; Vaccines, Subunit; Vaccines, Synthetic | 2007 |